(CercleFinance.com) – Nicox announced on Friday that royalties collected from Vyzulta, its ophthalmic solution licensed to Bausch + Lomb, had exceeded the threshold of four million euros for the first time in 2023.
The pharmaceutical company indicates that its turnover amounted to 4.2 million euros last year, an increase of 29% compared to the 3.3 million euros recorded during the financial year. 2022.
As of December 31, Nicox had cash of 11.9 million, compared to 27.7 million a year earlier, an amount considered sufficient to ensure its financing until June 2024, exclusively on the basis of the development of the NCX 470.
This novel nitric oxide donor prostaglandin analog is being studied for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension
In its press release, the company said it is continuing discussions on licensing and other revenue-generating agreements, while studying several strategic options and discussing with its creditors to restructure its debt, which amounts to 21 million euros.
Nicox emphasizes, however, that the approval and marketing of Zerviate (allergic conjunctivitis) planned in China in 2024 should also contribute to an increase in turnover from collaborations.
Listed on the Paris Stock Exchange, Nicox shares rose 0.8% on Thursday at mid-session following this publication, without much surprise.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
